Defunct Company
Total Trials
14
As Lead Sponsor
11
As Collaborator
3
Total Enrollment
562
NCT01630044
Neurostimulation Device for Treatment of Migraine Headache
Phase: N/A
Role: Lead Sponsor
Start: May 31, 2012
Completion: Apr 30, 2013
NCT01629901
Caloric Stimulation on Cerebral Blood Flow
Role: Collaborator
Start: Jun 30, 2012
Completion: Apr 30, 2015
NCT01899040
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Start: Aug 31, 2013
Completion: Jun 30, 2016
NCT02134795
A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease
Start: May 31, 2014
Completion: Sep 30, 2014
NCT02130401
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
Start: Jun 30, 2014
Completion: Jun 30, 2015
NCT02270866
Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia
Start: Oct 31, 2014
Completion: Jul 31, 2016
NCT02866084
Neuromodulation Treatment of Vestibular Migraines
Start: Sep 28, 2016
Completion: May 31, 2019
NCT02991430
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Start: Jun 30, 2017
Completion: May 11, 2018
NCT04797611
STEM-Parkinson's Disease
Start: May 19, 2022
Completion: Dec 6, 2024
NCT04799418
STEM-PD Open Label Extension (OLE)
Start: Sep 15, 2022
Completion: Feb 24, 2025
NCT05957484
The Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
Start: Sep 12, 2023
Completion: Feb 11, 2025
NCT05580211
Neuromodulation for Schizophrenia
Start: Oct 3, 2023
Completion: Jan 30, 2026
NCT05032482
WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
Start: Dec 31, 2023
Completion: Mar 31, 2024
NCT05987540
SHARPEN - Parkinson's Disease Dementia
Start: May 8, 2024